世界主要先進国における喘息治療薬市場（～2020）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Etiology 11
2.4 Pathophysiology 12
2.5 Symptoms 12
2.6 Diagnosis 12
2.7 Assessment of Disease Severity 13
2.8 Treatment 15
2.9 Treatment Algorithm 16
2.10 Treatment Segments 18
2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma 19
2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy 21
2.10.3 ICS/LABA Combination Therapy 22
2.10.4 Add-on Therapies 27

3 Marketed Products 33
3.1 Overview 33
3.2 ICS for the Maintenance Treatment of Asthma 33
3.2.1 Arnuity (fluticasone furoate) – GSK 33
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma 34
3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) – GSK 34
3.3.2 Symbicort (budesonide and formoterol fumarate) – AstraZeneca, Co-Promotion with Astellas Pharma 35
3.3.3 Dulera (mometasone furoate and formoterol fumarate) – Merck 36
3.3.4 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) – GlaxoSmithKline/Theravance 37
3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma 38
3.4.1 Xolair (omalizumab) – Novartis and Genentech 38
3.4.2 Singulair (montelukast) – Merck 39
3.4.3 Spiriva (tiotropium bromide) – Boehringer Ingelheim 40
3.5 Heat Maps for Marketed Products 42

4 Asthma Pipeline 44
4.1 Overview 44
4.2 Pipeline Analysis by Stage of Development, Molecule Type and Program Type 44
4.3 Pipeline Analysis by Molecular Target 46
4.4 Asthma Clinical Trial Landscape 53
4.4.1 Clinical Trial Failure Rates 53
4.4.2 Clinical Trial Duration 58
4.4.3 Clinical Trial Size 62
4.4.4 Comparative Clinical Trial Metrics Analysis 69
4.5 Promising Pipeline Molecules 71
4.5.1 Mepolizumab – GSK 71
4.5.2 Reslizumab – Teva Pharmaceutical 73
4.5.3 Lebrikizumab – Roche/Genentech 75
4.5.4 Dupilumab – Regeneron Pharmaceuticals in Collaboration with Sanofi 77
4.5.5 Masitinib – AB Science 79
4.6 Heat Map and Competitor Matrix for Pipeline Products 81

5 Market Forecast to 2020 84
5.1 Geographical Markets 84
5.2 Global Market 85
5.3 North America 88
5.3.1 Treatment Usage Patterns 88
5.3.2 Annual Cost of Therapy 90
5.3.3 Market Size 92
5.4 Top Five Countries of Europe 94
5.4.1 Treatment Usage Patterns 94
5.4.2 Annual Cost of Therapy 95
5.4.3 Market Size 97
5.5 Japan 98
5.5.1 Treatment Usage Patterns 98
5.5.2 Annual Cost of Therapy 98
5.5.3 Market Size 99
5.6 Drivers and Barriers for the Asthma Market 100
5.6.1 Drivers 100
5.6.2 Barriers 100

6 Strategic Consolidations 102
6.1 Co-development Deals 102
6.1.1 Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide 107
6.1.2 NeoStem Enters into Agreement with University of California to Develop Human Regulatory T Cells 108
6.1.3 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 108
6.2 Licensing Deals 108
6.2.1 Amgen Enters into Licensing Agreement with Kyowa Hakko Kirin – Terminated 115
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma 116
6.2.3 MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca – Terminated 116
6.2.4 Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals – Terminated 116
6.2.5 Aslan Pharma Enters into Licensing Agreement with CSL for CSL-334 117

7 Appendix 118
7.1 All Pipeline Drugs by Phase of Development 118
7.1.1 Discovery 118
7.1.2 Preclinical 119
7.1.3 Phase I 124
7.1.4 Phase II 125
7.1.5 Phase III 127
7.1.6 Pre-registration 128
7.2 Market Forecasts to 2020 128
7.2.1 Global 128
7.2.2 US 129
7.2.3 Canada 129
7.2.4 UK 129
7.2.5 France 130
7.2.6 Germany 130
7.2.7 Italy 130
7.2.8 Spain 131
7.2.9 Japan 131
7.3 References 131
7.4 Abbreviations 137
7.5 Research Methodology 137
7.5.1 Secondary Research 138
7.5.2 Marketed Product Profiles 138
7.5.3 Late-Stage Pipeline Candidates 139
7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 139
7.5.5 Product Competitiveness Framework 139
7.5.6 Pipeline Analysis 139
7.5.7 Forecasting Model 140
7.5.8 Deals Data Analysis 141
7.6 Expert Panel Validation 141
7.7 Contact Us 142
7.8 Disclaimer 142